JP2024533485A - がんの治療のためのＤＲ５標的化Ｍｕｌｔａｂｏｄｙ - Google Patents

がんの治療のためのＤＲ５標的化Ｍｕｌｔａｂｏｄｙ Download PDF

Info

Publication number
JP2024533485A
JP2024533485A JP2024516380A JP2024516380A JP2024533485A JP 2024533485 A JP2024533485 A JP 2024533485A JP 2024516380 A JP2024516380 A JP 2024516380A JP 2024516380 A JP2024516380 A JP 2024516380A JP 2024533485 A JP2024533485 A JP 2024533485A
Authority
JP
Japan
Prior art keywords
sequence
seq
cdr
self
polypeptide complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024516380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533485A5 (enExample
Inventor
ジャン－フィリップ ジュリアン，
ディエス， エドゥルネ ルハス
ジョアン ヒューム，
ピーター エドワード ベイリス，
シンウェン ヘ，
メリッサ バイルシュミット，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children
Original Assignee
Hospital for Sick Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hospital for Sick Children filed Critical Hospital for Sick Children
Publication of JP2024533485A publication Critical patent/JP2024533485A/ja
Publication of JP2024533485A5 publication Critical patent/JP2024533485A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2024516380A 2021-09-13 2022-09-13 がんの治療のためのＤＲ５標的化Ｍｕｌｔａｂｏｄｙ Pending JP2024533485A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163243372P 2021-09-13 2021-09-13
US63/243,372 2021-09-13
PCT/CA2022/051361 WO2023035084A1 (en) 2021-09-13 2022-09-13 Dr5-targeting multabodies for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024533485A true JP2024533485A (ja) 2024-09-12
JP2024533485A5 JP2024533485A5 (enExample) 2025-09-22

Family

ID=85507784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024516380A Pending JP2024533485A (ja) 2021-09-13 2022-09-13 がんの治療のためのＤＲ５標的化Ｍｕｌｔａｂｏｄｙ

Country Status (9)

Country Link
US (1) US20240409652A1 (enExample)
EP (1) EP4401790A4 (enExample)
JP (1) JP2024533485A (enExample)
KR (1) KR20240101550A9 (enExample)
CN (1) CN118317980A (enExample)
AU (1) AU2022344813A1 (enExample)
CA (1) CA3231176A1 (enExample)
MX (1) MX2024003139A (enExample)
WO (1) WO2023035084A1 (enExample)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528599A (ja) * 2010-05-14 2013-07-11 アムジェン インコーポレイテッド 増強デスレセプター・アゴニスト
WO2020252418A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants for the treatment of cancer
WO2021016724A1 (en) * 2019-08-01 2021-02-04 The Hospital For Sick Children Multi-valent and multi-specific nanoparticle platforms and methods
US20210054047A1 (en) * 2018-03-06 2021-02-25 Korea Institute Of Science And Technology Novel anticancer fusion protein and use thereof
WO2021081365A1 (en) * 2019-10-24 2021-04-29 Prometheus Biosciences, Inc. Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
WO2021173565A1 (en) * 2020-02-24 2021-09-02 Alector Llc Methods of use of anti-trem2 antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550191A (ja) * 2020-11-25 2023-11-30 ザ・ホスピタル・フォー・シック・チルドレン Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013528599A (ja) * 2010-05-14 2013-07-11 アムジェン インコーポレイテッド 増強デスレセプター・アゴニスト
US20210054047A1 (en) * 2018-03-06 2021-02-25 Korea Institute Of Science And Technology Novel anticancer fusion protein and use thereof
WO2020252418A2 (en) * 2019-06-14 2020-12-17 Cugene, Inc. Novel interleukin-2 variants for the treatment of cancer
WO2021016724A1 (en) * 2019-08-01 2021-02-04 The Hospital For Sick Children Multi-valent and multi-specific nanoparticle platforms and methods
WO2021081365A1 (en) * 2019-10-24 2021-04-29 Prometheus Biosciences, Inc. Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
WO2021173565A1 (en) * 2020-02-24 2021-09-02 Alector Llc Methods of use of anti-trem2 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DIVINE ET AL.: "Designed proteins assemble antibodies into molecular nanocages", SCIENCE, vol. Vol.372, Issue 6537, JPN7026003388, 2 April 2021 (2021-04-02), pages 9994, ISSN: 0005918253 *
LIU ET AL.: "Fc-Engineering for modulated effector functions-improving antibodies for cancer treatment", ANTIBODIES, vol. 9, JPN7026003389, 17 November 2020 (2020-11-17), pages 64, ISSN: 0005918254 *

Also Published As

Publication number Publication date
US20240409652A1 (en) 2024-12-12
WO2023035084A1 (en) 2023-03-16
KR20240101550A (ko) 2024-07-02
EP4401790A4 (en) 2025-09-03
AU2022344813A1 (en) 2024-04-11
EP4401790A1 (en) 2024-07-24
KR20240101550A9 (ko) 2025-12-10
CA3231176A1 (en) 2023-03-16
CN118317980A (zh) 2024-07-09
MX2024003139A (es) 2024-06-24

Similar Documents

Publication Publication Date Title
JP6731346B2 (ja) 標的ＴＧＦβ阻害
CN108884160A (zh) 抗ror1抗体
JP7682247B2 (ja) 抗ｂｃｍａ抗体及びその用途
JP2025541367A (ja) 多価および多重特異性サイトカインアンタゴニスト
JP2026500752A (ja) 抗ｂ７ｈ３抗体及びその使用方法
US20240409652A1 (en) Dr5-targeting multabodies for the treatment of cancer
JP2024533487A (ja) 最適化されたＭｕｌｔａｂｏｄｙ構築物、組成物、及び方法
JP2024535851A5 (enExample)
JP6869553B2 (ja) デスレセプター４及びデスレセプター５に結合する非常に強力な抗体
JP2025530261A (ja) マルタボディを使用する化学療法耐性腫瘍の処置
WO2024130395A1 (en) Multivalent hematopoietic cell engagers or activators
HK40130018A (en) Treatment of chemo-resistant tumors using multabodies
JP2025541366A (ja) 腫瘍壊死因子受容体アゴニスト性ｍｂ
HK40130677A (en) Multivalent hematopoietic cell engagers or activators
HK40130678A (en) Tumor necrosis factor receptor agonistic mbs
HK40130679A (en) Multivalent and multispecific cytokine antagonists
WO2025238528A1 (en) Tetravalent agonists of erythropoietin receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250911

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260728